BACKGROUND: There is a high incidence of hip fractures in patients with hemiplegic stroke. Bone mineral density (BMD) is decreased in the hemiplegic side in patients after stroke, correlating with the degree of paralysis and of hypovitaminosis D. OBJECTIVE: To evaluate the efficacy of risedronate in reducing the severity of osteoporosis and in decreasing the risk of hip fractures in elderly women following an acute stroke. METHODS: This was a 12-month, randomized, double blind, placebo-controlled trial. In a prospective study of stroke patients, 187 patients received a daily dose of 2.5 mg risedronate for 12 months, and the remaining 187 received placebo. Incidence of hip fracture was compared between the two groups at the endpoint of the study. RESULTS: Seven patients sustained hip fractures on the hemiplegic side in the placebo group, and one hip fracture occurred in the risedronate group (p = 0.0360; OR = 7.0). BMD increased by 1.5% and decreased by 4.9% in the risedronate group and placebo group (p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 53.4% in the risedronate group and increased by 35.8% in the placebo group. CONCLUSION: Treatment with risedronate increases bone mineral density in elderly women following an acute stroke and prevents hip fractures.
RCT Entities:
BACKGROUND: There is a high incidence of hip fractures in patients with hemiplegic stroke. Bone mineral density (BMD) is decreased in the hemiplegic side in patients after stroke, correlating with the degree of paralysis and of hypovitaminosis D. OBJECTIVE: To evaluate the efficacy of risedronate in reducing the severity of osteoporosis and in decreasing the risk of hip fractures in elderly women following an acute stroke. METHODS: This was a 12-month, randomized, double blind, placebo-controlled trial. In a prospective study of strokepatients, 187 patients received a daily dose of 2.5 mg risedronate for 12 months, and the remaining 187 received placebo. Incidence of hip fracture was compared between the two groups at the endpoint of the study. RESULTS: Seven patients sustained hip fractures on the hemiplegic side in the placebo group, and one hip fracture occurred in the risedronate group (p = 0.0360; OR = 7.0). BMD increased by 1.5% and decreased by 4.9% in the risedronate group and placebo group (p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 53.4% in the risedronate group and increased by 35.8% in the placebo group. CONCLUSION: Treatment with risedronate increases bone mineral density in elderly women following an acute stroke and prevents hip fractures.
Authors: Amy H Warriner; Ryan C Outman; Kenneth G Saag; Sarah D Berry; Cathleen Colón-Emeric; Kellie L Flood; Kenneth W Lyles; S Bobo Tanner; Nelson B Watts; Jeffrey R Curtis Journal: South Med J Date: 2009-04 Impact factor: 0.954
Authors: Kenneth E S Poole; Shobna Vedi; Irene Debiram; Collette Rose; Jon Power; Nigel Loveridge; Elizabeth A Warburton; Jonathan Reeve; Juliet Compston Journal: Bone Date: 2008-12-11 Impact factor: 4.398